Comparative Efficacy and Safety of Tezepelumab and Other Biologics in Patients with Inadequately Controlled Asthma According to Thresholds of Type 2 Inflammatory Biomarkers: A Systematic Review and Network Meta-Analysis

The anti-thymic stromal lymphopoietin antibody (tezepelumab) has therapeutical potential for inadequately controlled asthma. However, evidence comparing tezepelumab with other biologics is scarce. To address this issue, we performed a network meta-analysis to compare and rank the efficacy of five tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ando, Koichi, Fukuda, Yosuke, Tanaka, Akihiko, Sagara, Hironori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909778/
https://www.ncbi.nlm.nih.gov/pubmed/35269440
http://dx.doi.org/10.3390/cells11050819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909778/
https://www.ncbi.nlm.nih.gov/pubmed/35269440
http://dx.doi.org/10.3390/cells11050819

Ejemplares similares